Among the first evidences of a direct interaction between CDK-i and immunomodulation, there is the observation that CDK4 regulates PD-L1 protein stability and that combining CDK-i treatment with anti-PD-1 immunotherapy enhanced tumor regression and improved overall survival rates in mouse tumor models (64). The gene discussed is CD274; the disease is neoplasm.